Perturbations in eosinophil homeostasis following treatment of lymphatic filariasis.
Identifieur interne : 004B67 ( PubMed/Corpus ); précédent : 004B66; suivant : 004B68Perturbations in eosinophil homeostasis following treatment of lymphatic filariasis.
Auteurs : R. Gopinath ; L E Hanna ; V. Kumaraswami ; V. Perumal ; V. Kavitha ; V. Vijayasekaran ; T B NutmanSource :
- Infection and immunity [ 0019-9567 ] ; 2000.
English descriptors
- KwdEn :
- Adult, Animals, Case-Control Studies, Cell Degranulation (drug effects), Chemokine CCL5 (blood), Chemokines (blood), Cytokines (blood), Diethylcarbamazine (therapeutic use), Elephantiasis, Filarial (blood), Elephantiasis, Filarial (drug therapy), Eosinophils (drug effects), Eosinophils (physiology), Filaricides (therapeutic use), Flow Cytometry, Homeostasis, Humans, Interleukin-5 (blood), Male, Middle Aged, Time Factors, Wuchereria bancrofti.
- MESH :
- chemical , blood : Chemokine CCL5, Chemokines, Cytokines, Interleukin-5.
- blood : Elephantiasis, Filarial.
- drug effects : Cell Degranulation, Eosinophils.
- drug therapy : Elephantiasis, Filarial.
- physiology : Eosinophils.
- chemical , therapeutic use : Diethylcarbamazine, Filaricides.
- Adult, Animals, Case-Control Studies, Flow Cytometry, Homeostasis, Humans, Male, Middle Aged, Time Factors, Wuchereria bancrofti.
Abstract
Treatment of patients with patent Wuchereria bancrofti infection results in an acute clinical reaction and peripheral eosinophilia. To investigate the dynamics of the eosinophil response, changes in eosinophil activation and degranulation and plasma levels of eosinophil-active chemokines and cytokines were studied in 15 microfilaremic individuals in south India by sequential blood sampling before and after administration of 300 mg of diethylcarbamazine (DEC). Clinical symptoms occurred within 24 h. Plasma interleukin-5 (IL-5) and RANTES levels peaked 1 to 2 days posttreatment, preceding a peak peripheral eosinophil count at day 4. Major basic protein secretion from eosinophils paralleled IL-5 secretion, while levels of eosinophil-derived neurotoxin peaked at day 13 after treatment. Expression of the activation markers HLA-DR and CD25 on eosinophils rose markedly immediately after treatment, while expression of VLA-4 and alpha4beta7 showed an early peak within 24 h and a second peak at day 13. Thus, the posttreatment reactions seen in filarial infections can be divided into an early phase with killing of microfilariae, clinical symptomatology, increases in plasma IL-5 and RANTES levels, and eosinophil activation and degranulation and a later phase with expression of surface integrins on eosinophils, recruitment of eosinophils from the bone marrow to tissues, and clearance of parasite antigen.
PubMed: 10603373
Links to Exploration step
pubmed:10603373Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Perturbations in eosinophil homeostasis following treatment of lymphatic filariasis.</title><author><name sortKey="Gopinath, R" sort="Gopinath, R" uniqKey="Gopinath R" first="R" last="Gopinath">R. Gopinath</name><affiliation><nlm:affiliation>Helminth Immunology Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA. rgopinath@niaid.nih.gov</nlm:affiliation></affiliation></author><author><name sortKey="Hanna, L E" sort="Hanna, L E" uniqKey="Hanna L" first="L E" last="Hanna">L E Hanna</name></author><author><name sortKey="Kumaraswami, V" sort="Kumaraswami, V" uniqKey="Kumaraswami V" first="V" last="Kumaraswami">V. Kumaraswami</name></author><author><name sortKey="Perumal, V" sort="Perumal, V" uniqKey="Perumal V" first="V" last="Perumal">V. Perumal</name></author><author><name sortKey="Kavitha, V" sort="Kavitha, V" uniqKey="Kavitha V" first="V" last="Kavitha">V. Kavitha</name></author><author><name sortKey="Vijayasekaran, V" sort="Vijayasekaran, V" uniqKey="Vijayasekaran V" first="V" last="Vijayasekaran">V. Vijayasekaran</name></author><author><name sortKey="Nutman, T B" sort="Nutman, T B" uniqKey="Nutman T" first="T B" last="Nutman">T B Nutman</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2000">2000</date><idno type="RBID">pubmed:10603373</idno><idno type="pmid">10603373</idno><idno type="wicri:Area/PubMed/Corpus">004B67</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">004B67</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Perturbations in eosinophil homeostasis following treatment of lymphatic filariasis.</title><author><name sortKey="Gopinath, R" sort="Gopinath, R" uniqKey="Gopinath R" first="R" last="Gopinath">R. Gopinath</name><affiliation><nlm:affiliation>Helminth Immunology Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA. rgopinath@niaid.nih.gov</nlm:affiliation></affiliation></author><author><name sortKey="Hanna, L E" sort="Hanna, L E" uniqKey="Hanna L" first="L E" last="Hanna">L E Hanna</name></author><author><name sortKey="Kumaraswami, V" sort="Kumaraswami, V" uniqKey="Kumaraswami V" first="V" last="Kumaraswami">V. Kumaraswami</name></author><author><name sortKey="Perumal, V" sort="Perumal, V" uniqKey="Perumal V" first="V" last="Perumal">V. Perumal</name></author><author><name sortKey="Kavitha, V" sort="Kavitha, V" uniqKey="Kavitha V" first="V" last="Kavitha">V. Kavitha</name></author><author><name sortKey="Vijayasekaran, V" sort="Vijayasekaran, V" uniqKey="Vijayasekaran V" first="V" last="Vijayasekaran">V. Vijayasekaran</name></author><author><name sortKey="Nutman, T B" sort="Nutman, T B" uniqKey="Nutman T" first="T B" last="Nutman">T B Nutman</name></author></analytic><series><title level="j">Infection and immunity</title><idno type="ISSN">0019-9567</idno><imprint><date when="2000" type="published">2000</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Animals</term><term>Case-Control Studies</term><term>Cell Degranulation (drug effects)</term><term>Chemokine CCL5 (blood)</term><term>Chemokines (blood)</term><term>Cytokines (blood)</term><term>Diethylcarbamazine (therapeutic use)</term><term>Elephantiasis, Filarial (blood)</term><term>Elephantiasis, Filarial (drug therapy)</term><term>Eosinophils (drug effects)</term><term>Eosinophils (physiology)</term><term>Filaricides (therapeutic use)</term><term>Flow Cytometry</term><term>Homeostasis</term><term>Humans</term><term>Interleukin-5 (blood)</term><term>Male</term><term>Middle Aged</term><term>Time Factors</term><term>Wuchereria bancrofti</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Chemokine CCL5</term><term>Chemokines</term><term>Cytokines</term><term>Interleukin-5</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Cell Degranulation</term><term>Eosinophils</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Eosinophils</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Diethylcarbamazine</term><term>Filaricides</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Animals</term><term>Case-Control Studies</term><term>Flow Cytometry</term><term>Homeostasis</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Time Factors</term><term>Wuchereria bancrofti</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Treatment of patients with patent Wuchereria bancrofti infection results in an acute clinical reaction and peripheral eosinophilia. To investigate the dynamics of the eosinophil response, changes in eosinophil activation and degranulation and plasma levels of eosinophil-active chemokines and cytokines were studied in 15 microfilaremic individuals in south India by sequential blood sampling before and after administration of 300 mg of diethylcarbamazine (DEC). Clinical symptoms occurred within 24 h. Plasma interleukin-5 (IL-5) and RANTES levels peaked 1 to 2 days posttreatment, preceding a peak peripheral eosinophil count at day 4. Major basic protein secretion from eosinophils paralleled IL-5 secretion, while levels of eosinophil-derived neurotoxin peaked at day 13 after treatment. Expression of the activation markers HLA-DR and CD25 on eosinophils rose markedly immediately after treatment, while expression of VLA-4 and alpha4beta7 showed an early peak within 24 h and a second peak at day 13. Thus, the posttreatment reactions seen in filarial infections can be divided into an early phase with killing of microfilariae, clinical symptomatology, increases in plasma IL-5 and RANTES levels, and eosinophil activation and degranulation and a later phase with expression of surface integrins on eosinophils, recruitment of eosinophils from the bone marrow to tissues, and clearance of parasite antigen.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10603373</PMID><DateCreated><Year>2000</Year><Month>01</Month><Day>11</Day></DateCreated><DateCompleted><Year>2000</Year><Month>01</Month><Day>11</Day></DateCompleted><DateRevised><Year>2014</Year><Month>06</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0019-9567</ISSN><JournalIssue CitedMedium="Print"><Volume>68</Volume><Issue>1</Issue><PubDate><Year>2000</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Infection and immunity</Title><ISOAbbreviation>Infect. Immun.</ISOAbbreviation></Journal><ArticleTitle>Perturbations in eosinophil homeostasis following treatment of lymphatic filariasis.</ArticleTitle><Pagination><MedlinePgn>93-9</MedlinePgn></Pagination><Abstract><AbstractText>Treatment of patients with patent Wuchereria bancrofti infection results in an acute clinical reaction and peripheral eosinophilia. To investigate the dynamics of the eosinophil response, changes in eosinophil activation and degranulation and plasma levels of eosinophil-active chemokines and cytokines were studied in 15 microfilaremic individuals in south India by sequential blood sampling before and after administration of 300 mg of diethylcarbamazine (DEC). Clinical symptoms occurred within 24 h. Plasma interleukin-5 (IL-5) and RANTES levels peaked 1 to 2 days posttreatment, preceding a peak peripheral eosinophil count at day 4. Major basic protein secretion from eosinophils paralleled IL-5 secretion, while levels of eosinophil-derived neurotoxin peaked at day 13 after treatment. Expression of the activation markers HLA-DR and CD25 on eosinophils rose markedly immediately after treatment, while expression of VLA-4 and alpha4beta7 showed an early peak within 24 h and a second peak at day 13. Thus, the posttreatment reactions seen in filarial infections can be divided into an early phase with killing of microfilariae, clinical symptomatology, increases in plasma IL-5 and RANTES levels, and eosinophil activation and degranulation and a later phase with expression of surface integrins on eosinophils, recruitment of eosinophils from the bone marrow to tissues, and clearance of parasite antigen.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gopinath</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Helminth Immunology Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA. rgopinath@niaid.nih.gov</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hanna</LastName><ForeName>L E</ForeName><Initials>LE</Initials></Author><Author ValidYN="Y"><LastName>Kumaraswami</LastName><ForeName>V</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Perumal</LastName><ForeName>V</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Kavitha</LastName><ForeName>V</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Vijayasekaran</LastName><ForeName>V</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Nutman</LastName><ForeName>T B</ForeName><Initials>TB</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Infect Immun</MedlineTA><NlmUniqueID>0246127</NlmUniqueID><ISSNLinking>0019-9567</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018946">Chemokine CCL5</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018925">Chemokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005369">Filaricides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015848">Interleukin-5</NameOfSubstance></Chemical><Chemical><RegistryNumber>V867Q8X3ZD</RegistryNumber><NameOfSubstance UI="D004049">Diethylcarbamazine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>J Immunol. 1979 Jan;122(1):221-9</RefSource><PMID Version="1">570202</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Invest. 1991 Oct;88(4):1418-21</RefSource><PMID Version="1">1918387</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Trop Med Hyg. 1979 Sep;28(5):860-3</RefSource><PMID Version="1">484767</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Exp Med. 1979 Dec 1;150(6):1456-71</RefSource><PMID Version="1">390086</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Immunol. 1981 Sep;127(3):1093-8</RefSource><PMID Version="1">7021674</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lab Invest. 1984 Jan;50(1):51-61</RefSource><PMID Version="1">6363816</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Exp Med. 1992 Dec 1;176(6):1489-95</RefSource><PMID Version="1">1281207</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 1993 Jun;167(6):1396-400</RefSource><PMID Version="1">8501330</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Trop Med Hyg. 1993 Dec;49(6):804-11</RefSource><PMID Version="1">8279647</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Immunol Methods. 1993 Dec 3;166(2):183-90</RefSource><PMID Version="1">8288872</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Exp Med. 1994 Feb 1;179(2):703-8</RefSource><PMID Version="1">8294877</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Trop Med Hyg. 1994 Feb;50(2):206-9</RefSource><PMID Version="1">8116814</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Immunol. 1994 Sep 1;153(5):2153-60</RefSource><PMID Version="1">7519642</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Allergy Clin Immunol. 1994 Dec;94(6 Pt 2):1183-8</RefSource><PMID Version="1">7798558</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trans R Soc Trop Med Hyg. 1995 Jan-Feb;89(1):98-102</RefSource><PMID Version="1">7747322</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Exp Allergy. 1995 Aug;25(8):713-9</RefSource><PMID Version="1">7584682</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Parasitol Res. 1995;81(5):398-402</RefSource><PMID Version="1">7501639</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 1996 May;173(5):1277-80</RefSource><PMID Version="1">8627086</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Allergy Clin Immunol. 1996 Jun;97(6):1272-8</RefSource><PMID Version="1">8648023</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Scand J Immunol. 1996 Sep;44(3):229-38</RefSource><PMID Version="1">8795716</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Exp Immunol. 1996 Dec;106(3):462-7</RefSource><PMID Version="1">8973613</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Immunol. 1997 Feb 1;158(3):1332-44</RefSource><PMID Version="1">9013977</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Acta Trop. 1996 Dec 16;62(3):171-82</RefSource><PMID Version="1">9025985</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Invest. 1997 Mar 1;99(5):1064-71</RefSource><PMID Version="1">9062365</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int Arch Allergy Immunol. 1997 May-Jul;113(1-3):206-8</RefSource><PMID Version="1">9130524</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Haematol. 1997 Aug;98(2):312-4</RefSource><PMID Version="1">9266926</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int Arch Allergy Immunol. 1997 Oct;114 Suppl 1:14-7</RefSource><PMID Version="1">9363918</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int Arch Allergy Immunol. 1997 Oct;114 Suppl 1:81-3</RefSource><PMID Version="1">9363934</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cytometry. 1997 Dec 15;30(6):313-6</RefSource><PMID Version="1">9440823</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Immunol. 1998 Jan 1;160(1):351-60</RefSource><PMID Version="1">9551991</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Parasitol Res. 1998 Aug;84(8):607-15</RefSource><PMID Version="1">9747932</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Tropenmed Parasitol. 1984 Sep;35(3):177-82</RefSource><PMID Version="1">6495386</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Trop Med Hyg. 1985 May;34(3):529-36</RefSource><PMID Version="1">4003668</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Trop Med Hyg. 1985 Jul;34(4):735-45</RefSource><PMID Version="1">4025686</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>JAMA. 1988 Jun 3;259(21):3150-3</RefSource><PMID Version="1">3285045</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Science. 1989 Jul 21;245(4915):308-10</RefSource><PMID Version="1">2787531</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Immunol. 1990 Apr 15;144(8):3166-73</RefSource><PMID Version="1">2324497</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Immunol. 1990 May 15;144(10):3961-9</RefSource><PMID Version="1">2332637</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Exp Med. 1990 Jul 1;172(1):399-402</RefSource><PMID Version="1">2193099</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 1979 Mar;139(3):343-7</RefSource><PMID Version="1">448186</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015550" MajorTopicYN="N">Cell Degranulation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018946" MajorTopicYN="N">Chemokine CCL5</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018925" MajorTopicYN="N">Chemokines</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004049" MajorTopicYN="N">Diethylcarbamazine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004605" MajorTopicYN="N">Elephantiasis, Filarial</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004804" MajorTopicYN="N">Eosinophils</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005369" MajorTopicYN="N">Filaricides</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005434" MajorTopicYN="N">Flow Cytometry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006706" MajorTopicYN="N">Homeostasis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015848" MajorTopicYN="N">Interleukin-5</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014958" MajorTopicYN="Y">Wuchereria bancrofti</DescriptorName></MeshHeading></MeshHeadingList><OtherID Source="NLM">PMC97106</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1999</Year><Month>12</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1999</Year><Month>12</Month><Day>22</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1999</Year><Month>12</Month><Day>22</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10603373</ArticleId><ArticleId IdType="pmc">PMC97106</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004B67 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 004B67 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:10603373
|texte= Perturbations in eosinophil homeostasis following treatment of lymphatic filariasis.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:10603373" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |